

Table 37. Completion of Tuberculosis Therapy (COT): 59 Reporting Areas, 1999

Reporting Area	Total Cases	Therapy ≤1 Year Indicated ¹			Therapy >1 Year Indicated ²		Overall	
		No. ³	COT ≤1 Year(%)	COT(%)	No. ³	COT(%)	No. ³	COT(%)
United States	17,504	15,208	79.9	92.0	221	76.9	15,429	91.8
Alabama	314	260	80.4	94.6	1	100.0	261	94.6
Alaska	61	59	88.1	94.9	0	...	59	94.9
Arizona	262	231	82.7	95.7	3	100.0	234	95.7
Arkansas	181	156	82.7	89.7	0	...	156	89.7
California	3,606	3,187	79.1	92.2	52	73.1	3,239	91.9
Colorado	88	80	88.8	96.3	2	100.0	82	96.3
Connecticut	121	108	78.7	95.4	3	66.7	111	94.6
Delaware	34	30	83.3	93.3	0	...	30	93.3
District of Columbia	70	57	84.2	91.2	2	50.0	59	89.8
Florida	1,275	1,076	83.8	94.6	17	100.0	1,093	94.7
Georgia	670	594	77.3	88.7	7	71.4	601	88.5
Hawaii	184	168	67.3	85.1	2	0.0	170	84.1
Idaho	16	13	76.9	76.9	0	...	13	76.9
Illinois	822	700	81.3	90.1	8	100.0	708	90.3
Indiana	150	133	79.7	93.2	3	100.0	136	93.4
Iowa	58	54	81.5	87.0	1	100.0	55	87.3
Kansas	69	62	80.6	90.3	3	100.0	65	90.8
Kentucky	209	177	80.2	93.2	2	50.0	179	92.7
Louisiana	357	311	74.6	84.2	0	...	311	84.2
Maine	23	19	94.7	94.7	0	...	19	94.7
Maryland	292	256	86.3	93.4	7	57.1	263	92.4
Massachusetts	270	247	80.6	91.5	2	100.0	249	91.6
Michigan	349	293	83.6	96.9	8	87.5	301	96.7
Minnesota	201	184	87.5	96.2	5	80.0	189	95.8
Mississippi	215	187	84.0	94.1	0	...	187	94.1
Missouri	208	174	79.3	93.1	2	100.0	176	93.2
Montana	14	10	90.0	90.0	0	...	10	90.0
Nebraska	18	18	55.6	83.3	0	...	18	83.3
Nevada	93	81	77.8	82.7	1	100.0	82	82.9
New Hampshire	19	17	94.1	94.1	0	...	17	94.1
New Jersey	571	492	71.5	90.7	6	83.3	498	90.6
New Mexico	64	48	87.5	97.9	0	...	48	97.9
New York State ⁴	376	332	74.1	89.8	2	100.0	334	89.8
New York City	1,448	1,249	81.5	90.7	32	53.1	1,281	89.8
North Carolina	488	431	88.6	95.6	7	85.7	438	95.4
North Dakota	7	7	57.1	100.0	0	...	7	100.0
Ohio	317	262	71.4	90.1	1	100.0	263	90.1
Oklahoma	208	180	73.9	90.6	1	100.0	181	90.6
Oregon	123	114	78.1	89.5	1	100.0	115	89.6
Pennsylvania	453	370	75.7	91.1	8	75.0	378	90.7
Rhode Island	53	44	68.2	93.2	1	100.0	45	93.3
South Carolina	315	264	69.7	92.0	0	...	264	92.0
South Dakota	21	17	82.4	94.1	0	...	17	94.1
Tennessee	382	319	84.0	95.9	2	100.0	321	96.0
Texas	1,639	1,439	79.8	92.0	19	78.9	1,458	91.8
Utah	40	34	73.5	88.2	0	...	34	88.2
Vermont	3	2	50.0	100.0	0	...	2	100.0
Virginia	334	292	85.3	88.7	4	100.0	296	88.9
Washington	258	235	81.3	93.6	3	66.7	238	93.3
West Virginia	42	36	66.7	94.4	0	...	36	94.4
Wisconsin	110	96	86.5	97.9	3	66.7	99	97.0
Wyoming	3	3	100.0	100.0	0	...	3	100.0
American Samoa ⁵
Fed. States of Micronesia ⁵
Guam ⁵	69	65	0	...	65	...
N. Mariana Islands ⁵	66	62	82.3	83.9	0	...	62	83.9
Puerto Rico ⁵	200	148	82.4	94.6	1	100.0	149	94.6
Republic of Palau ⁵
U.S. Virgin Islands ⁵

¹Initial isolate susceptible to rifampin (n=11,516) or susceptibility unknown (n=328); culture-negative (n=2,541); culture status unknown (n=822); age unknown (n=1).

²Initial isolate rifampin resistant, or pediatric (aged <15) case with meningeal, bone or joint, or miliary disease.

³Number of cases in persons alive at diagnosis, with initial drug regimen of one or more drugs prescribed, who did not die during therapy. Percentage for U.S. based on 52 reporting areas (50 states, New York City, and the District of Columbia). Percentages shown only for reporting areas with information on reason therapy stopped reported for ≥90% of cases.

⁴Excludes New York City.

⁵Not included in U.S. totals.

Ellipses indicate data not available.

Note: See Technical Notes (Appendix A) for description of COT calculation.